By admin 
The research highlights a crucial paradox: while melatonin is globally embraced for its perceived benign nature and widespread availability, particularly in countries like the United States where it is sold over-the-counter, robust evidence regarding its extended use and potential systemic effects, especially on cardiovascular health, has remained remarkably sparse. This study aims to address that knowledge gap, raising pertinent questions for both healthcare providers counseling patients on sleep aids and individuals self-medicating for persistent insomnia.
The Ubiquity of Melatonin and its Physiological Role
Melatonin is a naturally occurring hormone synthesized primarily by the pineal gland in the brain. Its fundamental role is to regulate the body’s internal clock, known as the circadian rhythm, which dictates our sleep-wake cycle. Typically, melatonin levels surge as darkness falls, signaling to the body that it’s time to prepare for sleep, and diminish with the onset of daylight. Synthetic melatonin, chemically identical to its endogenous counterpart, has become a cornerstone for individuals grappling with various sleep challenges. Its primary applications include alleviating insomnia – characterized by difficulties in initiating or maintaining sleep – and mitigating the disruptive effects of jet lag.
The global market for sleep aids, with melatonin as a leading component, has seen exponential growth, driven by increasing awareness of sleep disorders and a societal shift towards self-care. In the U.S., melatonin’s status as a dietary supplement, rather than a drug, means it bypasses the stringent regulatory oversight of the Food and Drug Administration (FDA) that prescription medications undergo. This regulatory lacuna results in significant variability across brands regarding dosage accuracy, purity, and the presence of unlisted ingredients. Consumers often purchase these supplements with an implicit trust in their safety, unaware of the potential discrepancies between label claims and actual content. Conversely, in other nations, such as the United Kingdom, melatonin is classified as a prescription-only medication, reflecting a more cautious approach to its use and emphasizing medical supervision. This stark regulatory divergence further complicates the assessment of its real-world impact.
Investigating Long-Term Cardiovascular Risks
The impetus for this new study stemmed from the prevailing uncertainty surrounding melatonin’s cardiovascular safety when consumed over extended durations. Despite its widespread promotion as a safe and gentle sleep aid, comprehensive, long-term data on its potential cardiac ramifications has been conspicuously absent. This critical void propelled Dr. Ekenedilichukwu Nnadi, lead author of the study and chief resident in internal medicine at SUNY Downstate/Kings County Primary Care in Brooklyn, New York, and his research team to embark on this investigation. Their primary objective was to ascertain whether a sustained, long-term intake of melatonin could be correlated with an elevated risk of heart failure among individuals already contending with chronic insomnia.
Heart failure, often misunderstood as a complete cessation of heart function, is in fact a chronic, progressive condition where the heart muscle becomes unable to pump sufficient oxygen-rich blood to meet the body’s metabolic demands. This vital organ continues to beat, but inefficiently, leading to a cascade of symptoms including fatigue, shortness of breath, and fluid retention. The American Heart Association’s 2025 Heart Disease and Stroke Statistics underscore the gravity of this condition, reporting that it afflicts approximately 6.7 million adults in the U.S. annually, making any potential link to widely used supplements a matter of significant public health concern.
Study Design and Participant Cohorts
To conduct their investigation, the researchers leveraged the immense analytical power of the TriNetX Global Research Network. This expansive international database comprises de-identified electronic health records (EHRs), providing a rich tapestry of real-world patient data while meticulously safeguarding individual privacy. The study involved a retrospective analysis of five years of medical records pertaining to adult patients diagnosed with chronic insomnia.
Participants were meticulously categorized based on their documented melatonin usage. Individuals whose electronic medical records indicated at least one year of melatonin use were assigned to the "melatonin group." Conversely, those whose medical records contained no mention of melatonin use were allocated to the "non-melatonin group." A rigorous matching process was employed to ensure comparability between the two cohorts, accounting for various demographic and health parameters to minimize confounding factors. Critically, any individuals with a pre-existing diagnosis of heart failure or those who had been prescribed other sleep-inducing medications were systematically excluded from the study, thereby focusing the analysis on the potential new onset of heart failure specifically in relation to melatonin use.
"Melatonin supplements may not be as harmless as commonly assumed," remarked Dr. Nnadi. "If our study is confirmed through further research, these findings could profoundly influence how doctors approach patient counseling regarding over-the-counter sleep aids and necessitate a more cautious approach to their long-term use."
A Substantial Increase in Heart Failure Risk
The primary analysis yielded a statistically significant and clinically concerning disparity between the two groups. Among adults diagnosed with chronic insomnia, those with documented long-term melatonin use – defined as 12 months or more – exhibited an approximate 90% higher probability of developing heart failure over the subsequent five-year period when compared to their matched counterparts who did not use the supplement. Specifically, heart failure manifested in 4.6% of the melatonin group, starkly contrasting with 2.7% in the comparison group.
To bolster the confidence in these findings and address potential misclassification, particularly given the varying regulatory landscapes, the researchers conducted a secondary, more stringent analysis. This involved limiting the melatonin group to individuals who had filled at least two melatonin prescriptions with an interval of at least 90 days between them. This approach was particularly relevant for countries like the United Kingdom where melatonin is prescription-only, providing a stronger indication of consistent, sustained use. Even under this more rigorous criterion, the association persisted, with this subset of long-term users demonstrating an 82% elevated risk of developing heart failure. This consistency across different analytical approaches strengthens the validity of the observed correlation.
Beyond Heart Failure: Hospitalization and Mortality Risks
The study’s secondary analysis uncovered even more pronounced and alarming differences in other critical health outcomes, painting a more comprehensive picture of potential long-term risks. Individuals within the melatonin group faced nearly 3.5 times the likelihood of being hospitalized specifically for heart failure compared to those in the non-melatonin cohort. The hospitalization rates were 19.0% for melatonin users versus 6.6% for non-users, indicating a significantly higher burden on healthcare resources and a greater severity of cardiac events in the melatonin-using population.
Furthermore, the data revealed a concerning trend regarding all-cause mortality. Deaths from any cause were notably more prevalent among individuals with documented long-term melatonin use. Over the five-year observation period, 7.8% of participants in the melatonin group succumbed, in contrast to 4.3% in the non-melatonin group. This translates to nearly twice the risk of all-cause mortality for chronic melatonin users, a statistic that demands immediate attention and further investigation.
"Melatonin supplements are widely perceived as a benign and ‘natural’ option to support better sleep, so it was profoundly striking to observe such consistent and statistically significant increases in serious health outcomes, even after meticulously adjusting for numerous other established cardiovascular risk factors," Dr. Nnadi emphasized, underscoring the unexpected and impactful nature of their findings.
The results also resonated with other leading experts in sleep research. Marie-Pierre St-Onge, Ph.D., C.C.S.H., FAHA, a prominent sleep researcher not directly involved in this particular study, voiced her surprise and concern. "I’m surprised that physicians would prescribe melatonin for insomnia and have patients use it for more than 365 days, since melatonin, at least in the U.S., is not indicated for the treatment of chronic insomnia," she noted. "In the U.S., melatonin can be taken as an over-the-counter supplement, and people should be acutely aware that it should not be taken chronically without a proper medical indication and professional guidance." Dr. St-Onge, who chairs the writing group for the American Heart Association’s 2025 scientific statement, "Multidimensional Sleep Health: Definitions and Implications for Cardiometabolic Health," and serves as a professor of nutritional medicine and director of the Center of Excellence for Sleep & Circadian Research at Columbia University Irving Medical Center, highlights the critical distinction between short-term, specific use (e.g., jet lag) and prolonged, unmonitored self-medication for chronic insomnia. Her comments reinforce the need for greater awareness among both consumers and healthcare professionals about the appropriate and safe use of this widely available supplement.
Acknowledging Important Study Limitations
As with any observational research, this study comes with several significant limitations that warrant careful consideration and preclude drawing definitive cause-and-effect conclusions. One primary challenge arises from the international nature of the TriNetX database and the de-identified nature of the medical records, which prevented researchers from accessing participants’ geographical locations. This is crucial because melatonin’s regulatory status varies significantly across countries.
The reliance on electronic medical records for identifying melatonin use poses another potential source of misclassification. In countries like the U.S. where melatonin is available over-the-counter, individuals who purchased and consumed the supplement without it being recorded in their medical charts could have been erroneously categorized into the "non-melatonin group." If these unrecorded users were indeed taking melatonin and subsequently experienced adverse cardiac events, the study might have underestimated the true association, potentially diluting the observed risks. Conversely, simply having a prescription or a record of purchase does not guarantee consistent adherence, though the analysis requiring two prescriptions at least 90 days apart attempted to mitigate this.
Furthermore, there was a nuanced complication regarding the tracking of hospitalizations. The number of heart failure-related hospitalizations reported was higher than the number of newly diagnosed heart failure cases. This discrepancy arises because hospitals often input a range of related diagnostic codes during admissions, and these records do not consistently include a specific code that unequivocally identifies a new heart failure diagnosis. While this might inflate hospitalization figures, it still points to a greater burden of cardiac events requiring acute care in the melatonin group.
Crucially, the researchers lacked granular information concerning the severity of each participant’s insomnia or the presence of other psychiatric disorders such as depression or anxiety. These missing factors are significant potential confounders. Individuals experiencing more severe insomnia, or those grappling with co-occurring mental health conditions, might be more inclined to seek out and use melatonin for prolonged periods. These conditions, independent of melatonin use, are also known to be associated with an elevated cardiovascular risk. Therefore, it remains plausible that these underlying health issues, rather than melatonin itself, could contribute to the observed higher heart failure rates.
"Worse insomnia, depression/anxiety, or the use of other sleep-enhancing medicines might be linked to both melatonin use and heart risk," Dr. Nnadi acknowledged. "Also, while the association we found raises safety concerns about this widely used supplement, our study cannot prove a direct cause-and-effect relationship. This means more rigorous research, ideally in the form of prospective, randomized controlled trials, is urgently needed to thoroughly test melatonin’s safety for the heart and delineate any causal mechanisms."
Implications and Future Directions
Despite its limitations, this preliminary research serves as a vital "wake-up call" for the medical community and the general public alike. It challenges the prevailing assumption of melatonin’s absolute benignity, particularly in the context of chronic use. The findings underscore the critical importance of consulting healthcare professionals before embarking on long-term supplementation, even for seemingly innocuous over-the-counter products. For individuals currently using melatonin for chronic insomnia, these results suggest a need to re-evaluate its necessity and discuss alternative, evidence-based strategies for sleep improvement with their doctors.
Future research must prioritize well-designed, prospective studies, including randomized controlled trials where feasible, to definitively establish or refute a causal link between long-term melatonin use and adverse cardiovascular outcomes. Such studies would also be instrumental in exploring potential biological mechanisms by which melatonin might influence cardiac function, blood pressure regulation, or inflammatory pathways over time. Given the escalating global prevalence of sleep disorders and the burgeoning market for sleep aids, understanding the comprehensive long-term safety profile of widely used supplements like melatonin is not merely an academic exercise, but a paramount public health imperative. This study marks an important first step in that critical investigative journey.
